Hereditary spastic paraplegia SPG4: what is known and not known about the disease
Authors:
Open Access
- 20 June 2015
- journal article
- review article
- Published by Oxford University Press (OUP) in Brain
- Vol. 138 (9) , 2471-2484
Abstract
Mutations in more than 70 distinct loci and more than 50 mutated gene products have been identified in patients with hereditary spastic paraplegias, a diverse group of neurological disorders characterized predominantly, but not exclusively, by progressive lower limb spasticity and weakness resulting from distal degeneration of corticospinal tract axons. Mutations in the SPAST (previously known as SPG4) gene that encodes the microtubule-severing protein called spastin, are the most common cause of the disease. The aetiology of the disease is poorly understood, but partial loss of microtubule-severing activity resulting from inactivating mutations in one SPAST allele is the most postulated explanation. Microtubule severing is important for regulating various aspects of the microtubule array, including microtubule number, length, and mobility. In addition, higher numbers of dynamic plus-ends of microtubules, resulting from microtubule-severing events, may play a role in endosomal tubulation and fission. Even so, there is growing evidence that decreased severing of microtubules does not fully explain HSP-SPG4. The presence of two translation initiation codons in SPAST allows synthesis of two spastin isoforms: a full-length isoform called M1 and a slightly shorter isoform called M87. M87 is more abundant in both neuronal and non-neuronal tissues. Studies on rodents suggest that M1 is only readily detected in adult spinal cord, which is where nerve degeneration mainly occurs in humans with HSP-SPG4. M1, due to its hydrophobic N-terminal domain not shared by M87, may insert into endoplasmic reticulum membrane, and together with reticulons, atlastin and REEP1, may play a role in the morphogenesis of this organelle. Some mutated spastins may act in dominant-negative fashion to lower microtubule-severing activity, but others have detrimental effects on neurons without further lowering microtubule severing. The observed adverse effects on microtubule dynamics, axonal transport, endoplasmic reticulum, and endosomal trafficking are likely caused not only by diminished severing of microtubules, but also by neurotoxicity of mutant spastin proteins, chiefly M1. Some large deletions in SPAST might also affect the function of adjacent genes, further complicating the aetiology of the disease.Keywords
This publication has 93 references indexed in Scilit:
- Normal Spastin Gene Dosage Is Specifically Required for Axon RegenerationCell Reports, 2012
- Inhibition of Cell Migration and Cell Division Correlates with Distinct Effects of Microtubule Inhibiting DrugsJournal of Biological Chemistry, 2010
- ER sliding dynamics and ER–mitochondrial contacts occur on acetylated microtubulesJournal of Cell Biology, 2010
- Congenital bovine spinal dysmyelination is caused by a missense mutation in the SPAST geneneurogenetics, 2009
- A Class of Dynamin-like GTPases Involved in the Generation of the Tubular ER NetworkCell, 2009
- Structural basis for midbody targeting of spastin by the ESCRT-III protein CHMP1BNature Structural & Molecular Biology, 2008
- Expansion of mutation spectrum, determination of mutation cluster regions and predictive structural classification of SPAST mutations in hereditary spastic paraplegiaEuropean Journal of Human Genetics, 2008
- Structural basis of microtubule severing by the hereditary spastic paraplegia protein spastinNature, 2008
- Studying Nonsense-Mediated mRNA Decay in Mammalian Cells2008
- Interaction of two hereditary spastic paraplegia gene products, spastin and atlastin, suggests a common pathway for axonal maintenanceProceedings of the National Academy of Sciences, 2006